Impact of angiogenesis inhibitor eligibility on the prognosis of patients with non‐small cell lung cancer harboring EGFR mutation

BACKGROUND: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) are currently the primary treatment option for patients with EGFR‐mutant non‐small cell lung cancer (NSCLC). However, the effect of EGFR‐TKIs are eventually weakened due to resistance, and there is also a differentia...

Descripción completa

Detalles Bibliográficos
Autores principales: Kodama, Hiroaki, Kenmotsu, Hirotsugu, Kawabata, Takanori, Notsu, Akifumi, Yabe, Michitoshi, Nishioka, Naoya, Miyawaki, Eriko, Miyawaki, Taichi, Mamesaya, Nobuaki, Kobayashi, Haruki, Omori, Shota, Wakuda, Kazushige, Ono, Akira, Naito, Tateaki, Murakami, Haruyasu, Takahashi, Toshiaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8559472/
https://www.ncbi.nlm.nih.gov/pubmed/34587359
http://dx.doi.org/10.1002/cam4.4268

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8559472/
https://www.ncbi.nlm.nih.gov/pubmed/34587359
http://dx.doi.org/10.1002/cam4.4268

Ejemplares similares